Efficacy and safety evaluation of PSOX, DOF and SOX regimens as neoadjuvant chemotherapy for advanced gastric cancer

• Published in: Future oncology (London, England) Vol. 18; no. 40; pp. 4483 - 4492
• Main Authors: Yu, Pengjie, Zhu, Shengmao, Pu, Yongqiang, Cai, Baojia, Ma, Xiaoming, Zhang, Chengwu
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.12.2022
• Subjects: advanced gastric cancer; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Docetaxel - adverse effects; efficacy; Humans; neoadjuvant chemotherapy; Neoadjuvant Therapy; Oxaliplatin - adverse effects; Paclitaxel - adverse effects; PSOX; Retrospective Studies; safety; Stomach Neoplasms - drug therapy; Stomach Neoplasms - etiology; neoadjuvant chemotherapy; PSOX; advanced gastric cancer; safety; efficacy

To explore the efficacy and safety of paclitaxel+oxaliplatin+S-1 (PSOX), docetaxel+oxaliplatin+fluorouracil (DOF) and oxaliplatin+S-1 (SOX) regimens as neoadjuvant chemotherapy for advanced gastric cancer (GC). A retrospective analysis was used in 306 patients with GC who underwent neoadjuvant chemo...